Several previous studies [4, 15] has focused on auto-HSCT in patients with core binding factor (CBF) AML, including t(8;21)(q22;q22.1); RUNX1-RUNX1T1, inv(16)(p13.1q22) and t(16;16)(p13.1;q22); CBFB-MYH11, which accounts for 10–15% of all AML patients [16–18]. This evidence concerns the gene CBFB and acute myeloid leukemia.